
A phase III study in Indian T2DM patients shows that a triple fixed-dose combination (FDC) of dapagliflozin, glimepiride, and metformin ER significantly improves HbA1c levels compared to dual therapy. At 16 weeks, 52.6% of patients achieved HbA1c <7.0%. The triple FDC was well-tolerated, highlighting its potential for better glycemic control in inadequately controlled T2DM.
Like
Save
Share